Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating HCV infections
The present disclosure provides substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes, of Formula I D-M-D (Formula I) useful as antiviral agents. In certain embodiments disclosed herein M is a group —P-A-P— where A is Certain substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. Pharmaceutical compositions/and combinations containing one or more substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes and a pharmaceutically acceptable carrier are also provided by this disclosure. Methods for treating viral infections, including Hepatitis C viral infections are provided by the disclosure.
1. A compound of the formula:
2. A pharmaceutical composition comprising an effective amount of a compound of the formula:
to treat HCV in a patient diagnosed with HCV or its pharmaceutically acceptable salt, further comprising an additional active agent, in a pharmaceutically acceptable carrier.
3. The pharmaceutical composition of claim 2 , wherein the additional active agent is a protease inhibitor.
4. The pharmaceutical composition of claim 2 , wherein the additional active agent is a nucleoside analog.
5. The pharmaceutical composition of claim 2 , wherein the additional active agent is a NS5a inhibitor.
6. The pharmaceutical composition of claim 2 , wherein the additional active agent is a NS5b inhibitor.
7. The pharmaceutical composition of claim 2 , wherein the additional active agent is a NS4a inhibitor.
8. The pharmaceutical composition of claim 2 , wherein the additional active agent is a NS4b inhibitor.
9. The pharmaceutical composition of claim 2 , wherein the additional active agent is a polymerase inhibitor.
10. The pharmaceutical composition of claim 2 , wherein the additional active agent is a NS3a inhibitor.
11. The pharmaceutical composition of claim 2 , wherein the additional active agent is an immunomodulatory compound.
12. The pharmaceutical composition of claim 2 , in an oral dosage form.
13. The pharmaceutical composition of claim 3 , in an oral dosage form.
14. The pharmaceutical composition of claim 4 , in an oral dosage form.
15. The pharmaceutical composition of claim 5 , in an oral dosage form.
16. The pharmaceutical composition of claim 6 , in an oral dosage form.
17. The pharmaceutical composition of claim 7 , in an oral dosage form.
18. The pharmaceutical composition of claim 8 , in an oral dosage form.
19. The pharmaceutical composition of claim 9 , in an oral dosage form.
20. The pharmaceutical composition of claim 10 , in an oral dosage form.
21. The pharmaceutical composition of claim 11 , in an oral dosage form.
22. The pharmaceutical composition of claim 2 , in a tablet.
23. The pharmaceutical composition of claim 3 , in a tablet.
24. The pharmaceutical composition of claim 4 , in a tablet.
25. The pharmaceutical composition of claim 5 , in a tablet.
26. The pharmaceutical composition of claim 6 , in a tablet.
27. The pharmaceutical composition of claim 7 , in a tablet.
28. The pharmaceutical composition of claim 8 , in a tablet.
29. The pharmaceutical composition of claim 9 , in a tablet.
30. The pharmaceutical composition of claim 10 , in a tablet.
31. The pharmaceutical composition of claim 11 , in a tablet.
32. A method to treat HCV in a patient diagnosed with HCV with a pharmaceutical composition comprising a compound of the formula:
or its pharmaceutically acceptable salt, and further comprising an additional active agent optionally in a pharmaceutically acceptable carrier.
33. The method of claim 32 , wherein the additional active agent is a protease inhibitor.
34. The method of claim 32 , wherein the additional active agent is a nucleoside analog.
35. The method of claim 32 , wherein the additional active agent is a NS5a inhibitor.
36. The method of claim 32 , wherein the additional active agent is a NS5b inhibitor.
37. The method of claim 32 , wherein the additional active agent is a NS4a inhibitor.
38. The method of claim 32 , wherein the additional active agent is a NS4b inhibitor.
39. The method of claim 32 , wherein the additional active agent is a polymerase inhibitor.
40. The method of claim 32 , wherein the additional active agent is a NS3a inhibitor.
41. The method of claim 32 , wherein the additional active agent is an immunomodulatory compound.